PET Imaging in Prostate Cancer
Positron emission tomography (PET) is a highly sensitive tool for detecting and quantifying molecular activity throughout the body, and its use in oncology is now widespread. PET imaging is based on the detection of probes that consist at minimum of a targeting agent (e.g., an antibody, peptide, or small molecule) and a positron-emitting radionuclide that provides the signal for imaging. A variety of radionuclides with different half-lives are available for labeling, including fluorine 18 (18F), carbon 11 (11C), nitrogen 13 (13N), iodine 124 (124I), zirconium 89 (89Zr), and copper 64 (64Cu), and different radionuclides may be used to label the same targeting agent. The glucose analog fluorodeoxyglucose (FDG), labeled with 18F, is at present the most common PET radiotracer used in routine clinical care. However, a number of other probes now in the pipeline promise to significantly expand the role of PET in prostate cancer management. Furthermore, prostate-specific probes that can be imaged with PET have been identified and are undergoing clinical translation.
KeywordsProstate Cancer Positron Emission Tomography Androgen Receptor Positron Emission Tomography Imaging Prostate Stem Cell Antigen
- 42.Smith CJ (2003) Radiochemical investigations of gastrin-releasing peptide receptor-specific [(99m)Tc(X)(CO)3-Dpr-Ser-Ser-Ser-Gln-Trp-Ala-Val-Gly-His-Leu-Met-(NH2)] in PC-3, tumor-bearing, rodent models: syntheses, radiolabeling, and in vitro/in vivo studies where Dpr = 2,3-diaminopropionic acid and X = H2O or P(CH2OH)3. Cancer Res (Baltimore) 63:4082–4088.Google Scholar